Armando Tripodi1, Fabio Pellegatta2, Veena Chantarangkul3, Liliana Grigore4, Katia Garlaschelli4, Andrea Baragetti2, Laura Lemma3, Alberico Catapano5. 1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, IRCCS Cà Granda Ospedale Maggiore Foundation, Milano, Italy. Electronic address: armando.tripodi@unimi.it. 2. Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, Italy; Department of Pharmacological Sciences and Biomolecular, University of Milan, Milan, Italy. 3. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, IRCCS Cà Granda Ospedale Maggiore Foundation, Milano, Italy. 4. Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, Italy. 5. Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, Italy; Department of Pharmacological Sciences and Biomolecular, University of Milan, Milan, Italy; IRCCS Multimedica, Milano, Italy.
Abstract
OBJECTIVE: Statins are cholesterol-lowering agents with antithrombotic effect possibly unrelated to their lipid-lowering properties. Traditional global coagulation tests failed, however, to reveal clinically relevant change after treatment. We therefore sought to investigate whether statins were able to modify thrombin generation in hypercholesterolemia. METHODS: Fifty-one patients who needed treatment with statins were enrolled in this study. Thrombin generation, assessed as endogenous thrombin potential (the amount of thrombin generated after triggering coagulation with small amount of tissue factor) was measured at pre- and two months post-treatment with statins. RESULTS: The median (inter-quartile range) level of total cholesterol that was 325 mg/dL (278-405) decreased significantly [211 mg/dL (197-247)] at post-treatment (p<0.001); the median level of HDL cholesterol that was 49 mg/dL (43-56) increased significantly [55 mg/dL (47-66)] at post-treatment (p<0.001). The median endogenous thrombin potential (inter-quartile range) before treatment was 2372 nM·min (2008-2617) and decreased to 2,048 nM·min (1764-2375) (p<0.001) after treatment. CONCLUSION: The results support the hypothesis of a direct link between statins and coagulation through their capacity to lower thrombin generation in patients with hypercholesterolemia. PRACTICE IMPLICATIONS: The antithrombotic properties of statins could be mediated (at least in part) by their endogenous thrombin potential lowering effect. This interesting hypothesis warrants evaluation by clinical trials.
OBJECTIVE: Statins are cholesterol-lowering agents with antithrombotic effect possibly unrelated to their lipid-lowering properties. Traditional global coagulation tests failed, however, to reveal clinically relevant change after treatment. We therefore sought to investigate whether statins were able to modify thrombin generation in hypercholesterolemia. METHODS: Fifty-one patients who needed treatment with statins were enrolled in this study. Thrombin generation, assessed as endogenous thrombin potential (the amount of thrombin generated after triggering coagulation with small amount of tissue factor) was measured at pre- and two months post-treatment with statins. RESULTS: The median (inter-quartile range) level of total cholesterol that was 325 mg/dL (278-405) decreased significantly [211 mg/dL (197-247)] at post-treatment (p<0.001); the median level of HDL cholesterol that was 49 mg/dL (43-56) increased significantly [55 mg/dL (47-66)] at post-treatment (p<0.001). The median endogenous thrombin potential (inter-quartile range) before treatment was 2372 nM·min (2008-2617) and decreased to 2,048 nM·min (1764-2375) (p<0.001) after treatment. CONCLUSION: The results support the hypothesis of a direct link between statins and coagulation through their capacity to lower thrombin generation in patients with hypercholesterolemia. PRACTICE IMPLICATIONS: The antithrombotic properties of statins could be mediated (at least in part) by their endogenous thrombin potential lowering effect. This interesting hypothesis warrants evaluation by clinical trials.
Authors: Romy de Laat-Kremers; Augusto Di Castelnuovo; Lisa van der Vorm; Simona Costanzo; Marisa Ninivaggi; Chiara Cerletti; Dana Huskens; Amalia De Curtis; Alessandro Gialluisi; Cuicui Bai; Giovanni de Gaetano; Dongmei Yin; Maria Benedetta Donati; Bas de Laat; Licia Iacoviello Journal: Front Cardiovasc Med Date: 2022-06-16
Authors: Armando Tripodi; Rosa Lombardi; Massimo Primignani; Vincenzo La Mura; Flora Peyvandi; Anna L Fracanzani Journal: Biomedicines Date: 2022-01-24
Authors: Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska Journal: World J Gastroenterol Date: 2016-07-21 Impact factor: 5.742
Authors: Marie-Claire F Kleinegris; Joke Konings; Jan W Daemen; Yvonne Henskens; Bas de Laat; Henri M H Spronk; Arina J Ten Cate-Hoek; Hugo Ten Cate Journal: Front Cardiovasc Med Date: 2017-04-20